Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms ; volume:8 ; number:7 ; day:26 ; month:6 ; year:2018 ; pages:1-7 ; date:7.2018
Blood cancer journal ; 8, Heft 7 (26.6.2018), 1-7, 7.2018
- Urheber
-
De Stefano, Valerio
- Beteiligte Personen und Organisationen
-
Finazzi, Guido
Barbui, Tiziano
SpringerLink (Online service)
- DOI
-
10.1038/s41408-018-0101-8
- URN
-
urn:nbn:de:101:1-2018090218182705765657
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 01:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- De Stefano, Valerio
- Finazzi, Guido
- Barbui, Tiziano
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
New mouse models of myeloproliferative neoplasms
Myeloproliferative neoplasms : critical concepts and management
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
The Hematopoietic niche in myeloproliferative neoplasms
Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
New mouse models of myeloproliferative neoplasms
Myeloproliferative neoplasms : critical concepts and management
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
The Hematopoietic niche in myeloproliferative neoplasms
Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
New mouse models of myeloproliferative neoplasms
Myeloproliferative neoplasms : critical concepts and management
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms